GLP-1 supplements: what the label says, and what the evidence says

Why the shelf exists

Semaglutide and tirzepatide worked, and they are expensive, injected, and hard on the stomach. That combination created demand for something oral, cheap and gentle that could be described in the same breath. The supplement industry supplied it, and the fastest way to do so was to put “GLP-1” on the label.

S. Bryn Austin, professor at the Harvard T.H. Chan School of Public Health, describes the mechanism plainly: manufacturers put GLP-1 in the product name, and “any consumer that sees that will think, ‘Oh, it must work like Ozempic.’” Her assessment of the products themselves is that they “do not come close to matching the effectiveness of real GLP-1 agonists.”

The regulatory asymmetry is the whole story. A supplement does not need to prove it works before it is sold. As Austin puts it, “the FDA cannot require rigorous pre-screening for safety and certainly not for effectiveness because by law, these supplements cannot claim to be treating or curing or preventing disease.” Wegovy carries its evidence because it was made to earn approval. A capsule carries a disclaimer instead.

What the leading products actually claim

Read past the packaging to the basis each brand gives for its own numbers. Both of the biggest names are careful in ways the marketing around them is not.

Pendulum GLP-1 Probiotic

Pendulum says its strains — Akkermansia muciniphila and Clostridium butyricum — “can help boost that production” of GLP-1. The footnote on that sentence reads “Based on preclinical studies”, and the Clostridium butyricum data is described as internal Pendulum R&D from a cell-based assay. Preclinical means it has not been shown to do this in people.

The cravings figures are the ones that travel: 91% overall, 88% for sweets, 87% for carbs, 85% for fast food, 82% for high fat. Their footnote reads “Based on a consumer study of 274 people”. A consumer study is participants reporting how they felt. It has no placebo arm, so it cannot separate the product from the expectation of taking it.

Lemme Reset (GLP-1)

Lemme sells at $80 as a one-off or $64 a month on subscription, under the line “Clinically-Studied Ingredients Support GLP-1 Production, Appetite & Weight Management”. Read that carefully: the ingredients were studied, not the product. The blend is Morosil red orange 400 mg, Eriomin lemon 200 mg and Supresa saffron 176.5 mg per two capsules.

The supporting numbers are ingredient-level. Supresa is cited to an 8-week study described as double-blind and placebo-controlled, in which 69% of participants had decreased hunger and snacking events fell 55%. Eriomin is cited to a 12-week study that “increased GLP-1 levels”. Sample sizes and peer-review status are not given for any of them on the page.

To Lemme’s credit, the page states outright that the product “does not contain GLP-1 or synthetic GLP-1 and is not a GLP-1 agonist drug”, and carries the required notice that its statements “have not been evaluated by the Food and Drug Administration”. Both disclosures are accurate. Both sit below the claims that brought you there.

The Lemme price is worth sitting with. At $64 a month on subscription it costs roughly two thirds of the cheapest microdosed compounded semaglutide we verified, which is $99 a month at AgelessRx. One of those two things has phase-three trial data behind the molecule. The other has a consumer study and three ingredient studies of undisclosed size.

The ingredients, and what was actually found

Most of this category is built from a small set of ingredients that have been studied for weight loss for years, largely before anyone thought to attach them to GLP-1. The results are not a mystery. They are just small.

Chromium picolinate has the strongest showing, and it is worth reading what that means. A Cochrane review pooled 6 trials of 392 participants over 12 to 16 weeks and found −1.1 kg against placebo (95% CI −1.7 to −0.4), rating the quality of that evidence low. The authors’ own conclusion was that there is “no current, reliable evidence to inform firm decisions about the efficacy and safety” of it.

Glucomannan did worse. A randomised, double-blind, placebo-controlled trial gave 3.99 g a day for 8 weeks to 47 completers and found no significant difference from placebo. The authors reported it was “well tolerated but did not promote weight loss”.

Berberine, the one with the nickname, has the softest evidence of the three. NCCIH summarises the position as “not conclusive”, notes that many of the underlying studies had “a high risk of bias”, and reports that effects appeared mainly above 1 g a day for more than 8 weeks — a dose and duration most product labels do not reach.

The adulteration problem

The risk in this category is not only that a product does nothing. FDA runs a standing list of weight-loss products found to contain undeclared drug ingredients — most often sibutramine, a stimulant withdrawn from the US market in 2010 over cardiovascular risk. These are sold as supplements and are not supposed to contain a drug at all.

It is a tail risk rather than the norm, and it is concentrated in products sold through marketplaces and pop-up storefronts rather than established brands. But it is the specific reason a supplement bought on price alone is a different kind of gamble from a prescription filled by a named pharmacy. Check the FDA notification list before buying anything unfamiliar.

Where supplements do have a real role

There is a genuine version of this conversation, and it is almost the opposite of the marketing. It is not about replacing a GLP-1. It is about what to eat and take while you are on one.

The drugs work partly by making you eat less, and eating less means taking in less of everything. The recognised consequences are loss of lean mass alongside fat, thinner intake of protein and micronutrients, and constipation and dehydration from slowed gastric transit. Those are the problems worth spending money on, and the answers are unglamorous: enough protein, fibre, fluids and electrolytes, with anything else guided by actual bloodwork rather than a marketing page.

• ◆Protein is the one with a clear rationale — preserving lean mass during rapid weight loss is a real goal, and a shake is a practical way to hit a target when appetite is suppressed. Ask your prescriber for a number rather than taking one off a label.
• ◆Fibre and fluids address constipation, which is among the most common complaints on these drugs and one of the more common reasons people stop.
• ◆A multivitamin is defensible when intake has dropped substantially, and cheap enough that the downside is small.
• ◆Anything beyond that should follow a blood test showing a deficiency, not a supplement page describing one.

How to read a claim on this shelf

• ◆Find the asterisk. “Boosts GLP-1” with a footnote reading “based on preclinical studies” means it has not been shown to do that in people.
• ◆Ask what was studied — the finished product, or one ingredient in it. Ingredient studies do not transfer to a blend at a different dose.
• ◆A “consumer study” is people reporting how they felt. It is not a placebo-controlled trial and cannot separate a product from expectation.
• ◆A percentage without a denominator is not a result. “69% of participants” is only meaningful once you know how many there were.
• ◆Watch for the FDA disclaimer. It appears on every supplement by law, which makes it easy to skim past — but it is the manufacturer stating that no regulator has agreed with any of the above.
• ◆Check the price against the real thing. If a supplement costs within reach of the cheapest verified prescription route, the comparison it invites is one it loses.

The enforcement backdrop

Weight loss is one of the FTC’s standing enforcement priorities, and its guidance on health claims requires competent and reliable scientific evidence behind them. The agency also publishes a reference for media on spotting false weight-loss claims, which exists because the category reliably produces them.

The enforcement is not confined to pills. In July 2025 the FTC brought a case against telehealth provider NextMed over its GLP-1 weight-loss programme, alleging that its $138–$188 monthly price was not disclosed to exclude the GLP-1 drugs themselves, lab work and required consultations; that the one-year commitment and early termination fees were not adequately revealed; and that the company suppressed criticism by offering gift cards for the removal of negative reviews and conditioning refunds on their removal, alongside fabricated testimonials and before-and-after images. The final order was approved on 3 December 2025 with a $150,000 payment.

That case is a useful lens on the reviews elsewhere on this site. The conduct it describes — a headline price that turns out to exclude the medication, a commitment length that surfaces at cancellation, and a review page that has been curated — is exactly what the disclosure checklist here is built to detect.